Arizona Tribune - Boulevard

NYSE - LSE

CMSC	-0.09%	22.78	$
JRI	1.58%	12.67	$
BCC	2.69%	67.28	$
BCE	0.79%	24.17	$
CMSD	0.61%	22.89	$
NGG	0.67%	84.72	$
GSK	-0.53%	50.78	$
BTI	-1.16%	65.3	$
RIO	2.31%	103.31	$
RBGPF	1.14%	63.23	$
RYCEF	5.42%	16.25	$
BP	-2.24%	45.13	$
AZN	1.5%	187.46	$
RELX	0.06%	33.6	$
VOD	0.59%	15.24	$

Featured

UN members reinforce nations' climate change obligations

The United Nations General Assembly on Wednesday adopted a resolution reinforcing states' obligations to combat climate change, a long-awaited move toned down under pressure from major greenhouse gas emitters.

Ubisoft counts cost of restructuring with record annual loss

French games giant Ubisoft on Wednesday reported a record annual loss of almost 1.5 billion euros ($1.7 billion) for its 2025-26 financial year, in the midst of a far-reaching restructuring, game delays and cancellations.

Last news

Campaigners warn Italy's gutted rape bill could help assailants

An attempt in Italy to introduce a consent-based rape law is floundering and experts warn rapists could stand to gain after the far right torpedoed an "only yes means yes" definition.

Libyan ex-prison boss faces ICC war crimes hearing

A former boss of a notorious Libyan prison faces three days of hearings at the International Criminal Court from Tuesday, accused of war crimes including murder, rape and torture.

Star of Rome's 'sexy priest' calendar admits: 'I was never a priest'

His face smiles out from every kiosk in Rome on the cover of the ubiquitous "sexy priest" calendar sold to tourists but Giovanni Galizia was never a man of the cloth.

Onco-Innovations Reports Continued Advancement of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for ONC010 Development Program

VANCOUVER, BC / ACCESS Newswire / May 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news release dated April 28, 2026, continued progress in the intermediate1 scale-up and process development activities for the A83 and B4 precursor components supporting the Company's lead oncology program, ONC010, a novel nanoparticle-formulated PNKP inhibitor currently advancing through IND-enabling development.

Wellgistics Health Reports First Quarter 2026 Financials and Provides Business Update

Wellgistics Pharmacy monthly revenue increased from approximately $0.1 million in November 2025 to approximately $0.6 million in April 2026, based on preliminary unaudited resultsQ1-26 focus on optimization of Wellgistics Pharmacy revenue growth and capabilities positions Company to integrate emerging licensed PharmacyChain™ pharmacy data tokenization technology into pharmacy dispensing AI hub EinsteinRx™Kare Pharmtech joint venture expands the Company's telepharmacy and direct-to-patient capabilities, providing immediate access to 200,000+ patient livesStrategic partnership with Tollo Health provides access to proprietary pharmaceutical-adjunct medical foods & dietary supplements, telemedicine and mental health AI coaching & regimen compliance tools via "Health Lives Here" app that is targeted to launch in August 2026 following the reveal with NFL Alumni Health at 2026 NFL Draft in PittsburghThe Company is in advanced discussions with Datavault AI regarding a binding term sheet to expand the scope of the PharmacyChain™ license to include Health-as-a-Service (HaaS) capabilitiesCompany has terminated previously announced non-binding letters of intent with Neuritek and WellCare and does not intend to proceed with those transactions

Squeeze Launches PeelVoice to Bring Full-Funnel Visibility to Customer Conversations

New conversation intelligence platform helps marketing, sales, QA, and leadership teams turn every call into clearer insight, smarter action, and measurable performance improvement.

Bouka Family Sets Out Again to Conquer Everest

Inspiring resilience

Trustpoint Xposure Trustpoint Xposure Establishes New York Headquarters, Positioning the AEO-Certified PR Agency at the Center of the AI Search Revolution

The only PR agency that guarantees brand placement inside AI-generated answers brings its full methodology to New York, the most competitive professional market in the world.

Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat

NEW YORK CITY, NY / ACCESS Newswire / May 19, 2026 / New to The Street's longtime featured biotechnology client, Acurx Pharmaceuticals, Inc. (Nasdaq:ACXP), highlighted a potentially transformative regulatory development for companies developing therapies targeting Clostridioides difficile infection (CDI), as the U.S. Food and Drug Administration finalized updated guidance that may significantly streamline the path toward approval for new CDI antibiotics.

Herbert Hoover Presidential Library and Museum to Celebrate Grand Reopening August 6, 2026

WEST BRANCH, IA / ACCESS Newswire / May 19, 2026 / The Hoover Presidential Foundation announced today the grand reopening of the newly renovated Herbert Hoover Presidential Library and Museum on Thursday, August 6, 2026, in West Branch, Iowa.

Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering

$6.0 million upfront with up to an additional approximately $12.0 million of potential aggregate gross proceeds upon the exercise in full of warrants.

AP Technologies Acquires Blueacre Technology, Adding Nitinol and Precision Laser Processing to Its Catheter Platform

Acquisition extends AP Technologies' vertically integrated catheter platform into nitinol and precision laser processing. Dundalk, Ireland joins the company's network of Centers of Excellence as its first European operation.

Medical Care Technologies (OTC PINK:MDCE) Positions Its Next-Generation AI Strategy Amid Rapid Breakthroughs from NVIDIA and Anthropic

Rapid advances in artificial intelligence may create new opportunities for MDCE to expand technical capability while accelerating execution across its AI platform initiatives.

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7

KELOWNA, BC / ACCESS Newswire / May 19, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that ethics approval has been received from an independent review board, for Human Pilot Study #7 (GLP-1-H26-7) that will evaluate two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo Nordisk's® commercially available Wegovy® tablets (the "Study").

Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer

First MVID patient enters the active treatment only extension phase after completion of randomized double-blind crossover period to evaluate longer-term safety and efficacy with liquid oral crofelemer as adjunctive treatment for MVID, an ultrarare pediatric disease with a lethal natural history and no approved therapies, requiring lifelong parenteral support (PS)

CLS Health Helps Child Born with Three Rare Conditions to Walk Normally

A case study from the Houston region's leading physician-owned healthcare group delivered a life-changing intervention for a child born with a rare combination of Moebius syndrome, Poland syndrome and severe clubfoot.

Europe's Hospital Cybersecurity Hot Zones and Top Cyber Vendors as EHR and EPR Attacks Shift From Data Theft to Care Disruption

Recent European hospital incidents, NIS2 accountability, EPR exposure, supplier concentration, and 72-hour downtime weakness are pushing buyers toward clinical-continuity cybersecurity ahead of HIMSS26 Europe

Empirical Spine Announces First Commercial LimiFlex(R) Cases at Stanford Medicine, Marking U.S. Launch of Motion-Preserving Alternative to Fusion for Degenerative Spondylolisthesis

First U.S. commercial cases establish LimiFlex as an outpatient, motion-preserving stabilization option

Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner

NEW YORK, NY / ACCESS Newswire / May 19, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing novel peptide-based therapies for stress-related neuropsychiatric disorders, today announced two strategic engagements to support the advancement of its lead candidate, PT00114. The Company has engaged Floyd Regulatory Strategic Consulting, led by regulatory affairs veteran Dr. Eric Floyd, Ph.D., MBA, as Regulatory Affairs Advisor, and DanforthHealth, a premier life science operational consulting firm, to establish institutional-grade operational processes and infrastructure. Together, these engagements reflect Protagenic's deliberate, lean operating model concentrating resources and expertise on PT00114's Phase 2 advancement while positioning the Company for long-term value creation for patients and shareholders.

Off The Hook YS To Rebrand as NextBoat and Change Ticker Symbol to "NXB"

WILMINGTON, NC / ACCESS Newswire / May 19, 2026 / Off The Hook YS Inc. (NYSE American:OTH) ("Off the Hook Yachts" or "Off the Hook" or "the Company"), a vertically integrated, AI-powered marine marketplace and one of the largest buyers and sellers of used boats in the United States, today announced that it will officially rebrand as NextBoat Inc. and change its ticker symbol from "OTH" to "NXB" on the NYSE American, effective on or about May 29, 2026.

Black Book Research Releases State of Digital Healthcare IT 2026: Norway Market Report

New report analyzes Norway's digital health infrastructure, EHR modernization, national e-health platforms, interoperability, AI, cybersecurity, municipal care technology, and healthcare IT vendor landscape through 2030

BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development

VANCOUVER, BC / ACCESS Newswire / May 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that its Semaglutide oral dissolvable film ("ODF") program has entered the active pharmaceutical development phase in collaboration with German drug development partner Gen-Plus GmbH.

InterContinental Hotels Group PLC Announces Transaction in Own Shares - May 19

Purchase of own shares

Harry Styles fans to splash over £1 bn on London concerts: Barclays

Harry Styles' dozen concerts in London this summer will see fans spend more than £1.0 billion ($1.3 billion) combined on tickets and costs including accommodation and travel, Barclays forecast Tuesday.

Three killed in San Diego mosque shooting, two attackers dead

A shooting at a mosque complex in California killed three people Monday, with two suspected teenage gunmen later found dead in a car from self-inflicted gunshot wounds, police said.

After mayor's murder, Mexico battles to bring peace

The brazen murder of a small-city mayor shocked Mexico and forced President Claudia Sheinbaum to step up an offensive against all-powerful drug cartels.

Musk loses blockbuster OpenAI suit as jury says too late

A federal jury ruled Monday that Elon Musk waited too long to sue OpenAI and its co-founders, delivering a decisive victory to OpenAI CEO Sam Altman and ending one of Silicon Valley's most closely watched courtroom battles.

First attack on Arab nuclear site sends warning to Gulf, US

The first attack targeting an Arab nuclear site has sent a symbolic warning to the United Arab Emirates and its allies, even as Iran and the US remain in negotiations to end the Middle East war, analysts say.

Hantavirus-hit cruise ship docks in Rotterdam at voyage end

A cruise ship that sparked global alarm after a deadly outbreak of hantavirus docked in Rotterdam harbour Monday, with the skeleton crew facing weeks of quarantine.

Train driver charged after deadly Bangkok bus collision

The driver of a train that collided with a bus in Thailand's capital, killing eight people, has tested positive for drugs and was charged with reckless driving, police said Monday.

Encroaching world threatens India's last 'uncontacted' tribe

One of the last outsiders to make authorised visits to India's only "uncontacted" tribe says it may be time to reconnect with the isolated people -- in order to shield them from an encroaching world.

Four takeaways from Musk vs OpenAI trial

After three weeks of intense hearings,Silicon Valley's first major AI trial -- over the lawsuit filed by Elon Musk against the co-founders of OpenAI -- is nearing an end. It is expected to go to the jury on Monday.

Arizona Tribune - Boulevard (English)